Market Overview

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Share:

Three Biotechnology Companies Added to the Index

Loncar Investments, LLC today announced the result of the semi-annual
rebalance and reconstitution of the Loncar
Cancer Immunotherapy Index
, a stock index of the top 30 companies
developing cancer immunotherapy treatments and discovering new ways to
use the body's immune system to fight cancer.

The Committee has added Idera Pharmaceuticals (NASDAQ:IDRA), Nektar
Therapeutics (NASDAQ:NKTR) and Pieris Pharmaceuticals (NASDAQ:PIRS) to
the index.

These additions replace Advaxis (NASDAQ:ADXS), Curis (NASDAQ:CRIS) and
Syndax Pharmaceuticals (NASDAQ:SNDX).

"Immunotherapy delivered important advances to cancer treatment this
year, including gaining first-time FDA approvals to treat types of
colorectal, gastric and lung cancers, as well as hepatocellular
carcinoma, Merkel cell carcinoma, leukemia and lymphoma," said Brad
Loncar, CEO of Loncar Investments and Chairman of the index committee.
"We are proud of the critical roles that our index constituents have
played in the advancement of immunotherapy and welcome these three new
additions that bring innovative and unique approaches to the field."

Effective this week, all index holdings have been rebalanced to hold
equal weight. The index is rebalanced and reconstituted semi-annually.
The next rebalance will occur on June 19, 2018.

Loncar Investments is an official partner of the Cancer
Research Institute
, the world's longest running nonprofit
organization dedicated exclusively to harnessing the immune system's
power to conquer all cancers. To learn about how to donate to CRI,
please visit here.

Why immunotherapy: Cancer immunotherapy has become an important
sector in the biotechnology space and is changing the way many cancers
are treated. While traditional medicines like chemotherapies often give
cancer a broad punch, the benefit of using immunotherapy is derived from
the immune system's dynamic nature and the way it can more precisely be
tailored to fight a patient's disease.

About the index: The Loncar Cancer Immunotherapy Index is an
equal-weighted index of 30 top immunotherapy companies rebalanced and
reconstituted on a semi-annual basis. Price and return data are
independently calculated on a daily basis by Indxx, LLC. This is a
sector index similar to Technology sector indices (Internet, Cyber
Security, Robotics, etc.). Sector indices allow investors to track
interest areas more precisely than broad indices. Additional information
can be found at the index's dedicated website, www.LoncarIndex.com.

Index provider: Loncar Investments, LLC is committed to making
the biotechnology space more approachable to a wider range of investors.
The company is principally owned by biotech investor and analyst Brad
Loncar. Mr. Loncar manages a biotech-focused family portfolio from his
Lenexa, Kan. office. He can be followed on Twitter at @bradloncar
and his commentary is available at www.loncarblog.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com